(Bloomberg) -- The jury mulling the fate of Retrophin Inc. co-founder Martin Shkreli ended the third day of deliberations without a peep.
On Tuesday, the panel had asked for the definitions of "assets under management" and "fraudulent intent," but it didn't communicate with the court on Wednesday.
The 34-year-old Shkreli, known as "Pharma Bro," is accused of taking money from investors in his previous hedge funds and using it to start Retrophin, then using the drug-development company's cash to pay them back. He faces as long as 20 years in prison if convicted of the most serious charges against him.
The case is U.S. v. Shkreli, 15-cr-0637, U.S. District Court, Eastern District of New York (Brooklyn).
To contact the reporter on this story: Chris Dolmetsch in New York State Supreme Court in Manhattan at cdolmetsch@bloomberg.net.
To contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Joe Schneider, Paul Cox
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
